logo-loader
Scancell Holdings PLC

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

patent spelled out in coloured letters
The company now has protection in many of its key markets

Scancell Holdings PLC (LON:SCLP) shares rose on Monday after the group revealed it has won Japanese patent protection for its Moditope immunotherapy platform.

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia, and acceptance for a grant in China.

READ: Scancell strengthens IP with two “important” patent grants in US and Europe

“We look forward to continuing to advance Modi-1, the first product from this platform, towards clinical development," said chief executive, Dr Cliff Holloway.

Moditope is one of two platforms the company has developed – the other is ImmunoBody, which has spawned SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda checkpoint inhibitor to treat patients with advanced melanoma.

In mid-morning trading, shares in Scancell were up 2% at 5.2p.

 -- Adds share price --

Quick facts: Scancell Holdings PLC

Price: £0.07

Market: LSE
Market Cap: £32.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital...

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital Conference 

on 03/08/2016

2 min read